Companies › Genrix (Shanghai) Biopharmaceutical
4 active drug programs in 9 registered trials: 3 Phase 3, 3 Phase 2, 3 Phase 1; Immunology, Oncology, Other, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GR1803 injection | – | Phase 3 | Multiple Myeloma; Multiple Myleoma; Systemic Lupus Erthematosus | May 2027 |
| GR1802 anti-IL4Rα monoclonal antibody | IL4R | Phase 3 | Allergic Rhinitis, Seasonal; Chronic Rhinosinusitis With Nasal Polyps; Allergic Rhinitis | – |
| GR2303 injection | – | Phase 1 | Health Adult Subjects | Dec 2026 |
| GR1603 Anti-IFNAR1 monoclonal antibody | IFNAR1 | Phase 1 | Lupus Erythematosus, Systemic | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06315426 | GR1802 | Phase 2 | Allergic Rhinitis | Immunology | May 2025 |
| NCT07154342 | GR1802 | Phase 3 | Allergic Rhinitis, Seasonal | Immunology | Apr 2026 |
| NCT06516302 | GR1802 | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Jun 2026 |
| NCT07199270 | GR2303 injection | Phase 1 | Health Adult Subjects | Other | Dec 2026 |
| NCT06566547 | GR1803 injection | Phase 2 | Multiple Myeloma | Oncology | May 2027 |
| NCT07348055 | GR1803 injection | Phase 1 | Systemic Lupus Erthematosus | Immunology | Jun 2027 |
| NCT06952075 | GR1803 injection | Phase 2 | Multiple Myleoma | Oncology | Jul 2027 |
| NCT06015230 | GR1603 | Phase 1 | Lupus Erythematosus, Systemic | Immunology | Jun 2028 |
| NCT07452198 | GR1803 injection | Phase 3 | Multiple Myeloma | Oncology | Mar 2029 |
Anterogen Keymed Biosciences Co.Ltd Apogee Therapeutics Direct Biologics Inmunotek
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.